Lymphoma — Expanded Access Programs
Overview
Right2Hope maintains a directory of 58 expanded access programs, clinical trials, and compassionate use pathways listed for Lymphoma. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with lymphoma programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 23 programs are currently active or recruiting, with the remaining 35 in other lifecycle stages. Sponsors actively running programs in this area include M.D. Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI), Center for International Blood and Marrow Transplant Research, Beth Israel Deaconess Medical Center, and others.
By recruiting status
Snapshot of where every Lymphoma program currently sits in its lifecycle.
- Active / Recruiting23
- Inactive35
Top sponsors
Organisations running the most Lymphoma programs in the directory.
- M.D. Anderson Cancer Center9 programs
- Memorial Sloan Kettering Cancer Center8 programs
- National Cancer Institute (NCI)4 programs
- Center for International Blood and Marrow Transplant Research3 programs
- Beth Israel Deaconess Medical Center2 programs
- Gottfried von Keudell, MD PhD2 programs
- Hoffmann-La Roche2 programs
- Masonic Cancer Center, University of Minnesota2 programs
- University of Chicago2 programs
- Alliance for Clinical Trials in Oncology1 program
Lymphoma programs (58)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Phase 2 Study of Mosunetuzumab and Zanubrutinib for Patients with Returning or Hard-to-Treat Marginal Zone Lymphoma — M.D. Anderson Cancer Center
- Study on Preventing Graft-Versus-Host Disease in Patients Receiving Stem Cell Transplants from Unrelated Donors — Center for International Blood and Marrow Transplant Research
- Study on Carmustine With and Without Ethanol for Lymphoma Patients — VIVUS LLC
- Study on CPI-613 for Patients with Difficult or Returning Burkitt Lymphoma/Leukemia or High-Risk B-Cell Lymphoma — Memorial Sloan Kettering Cancer Center
- Study on Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People with HTLV-1 — Memorial Sloan Kettering Cancer Center
- Study on the Effectiveness and Safety of Lisocabtagene Maraleucel (Liso-cel) as Initial Treatment for Adults with Primary Central Nervous System Lymphoma Who Cannot Have a Transplant — Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Study on Glofitamab with Rituximab and Chemotherapy for High-Risk Patients with Untreated Diffuse Large B-Cell Lymphoma — Hoffmann-La Roche
- Study on Abatacept with Cord Blood Transplant for Preventing Acute Graft Versus Host Disease — Leland Metheny
- BRAZAN Trial for Initial Treatment of Mantle Cell Lymphoma (MCL) — Christine Ryan
- Study on Adding Capivasertib to Chemotherapy and Venetoclax for Adults with ALL/LBL — University of Chicago
- Study on Chemotherapy With or Without Stem Cell Transplant for Treating Central Nervous System B-Cell Lymphoma — Alliance for Clinical Trials in Oncology
- Study on Lenalidomide and Rituximab Combination for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL) — M.D. Anderson Cancer Center
- Study on Combination Therapy with Entinostat and Pembrolizumab for Relapsed and Hard-to-Treat Lymphomas — Memorial Sloan Kettering Cancer Center
- Cord Blood Transplantation for Children and Young Adults with Blood Cancer — Memorial Sloan Kettering Cancer Center
- Study on Defining Blood Test Metrics in Posttransplant Lymphoproliferative Disorder (PTLD) — Jennifer Amengual
- Study on Epcoritamab for Follicular Lymphoma Patients Not Achieving Complete Response with Initial Chemoimmunotherapy — Beth Israel Deaconess Medical Center
- Study on Epcoritamab, Zanubrutinib, and Rituximab for Treating Relapsed or Refractory Follicular Lymphoma — Reid Merryman, MD
- Study on Mosunetuzumab for Clearing Minimal Residual Disease in Chronic Lymphocytic Leukemia (CLL) — Inhye Ahn
- Study on ASTX660 for Patients with Advanced Solid Tumors and Lymphomas — Taiho Oncology, Inc.
- Study on the Safety and Dosage of Neratinib for Children and Young Adults with Cancer That Has Returned or Not Responded to Treatment — Memorial Sloan Kettering Cancer Center
- Study on SGN-35 for Treating CD30-positive Skin Lymphomas — M.D. Anderson Cancer Center
- Study on Genetic Testing-Directed Targeted Therapy for Advanced Solid Tumors, Lymphomas, or Multiple Myeloma — National Cancer Institute (NCI)
- The CARDIOPROTECT Trial: Comparing Heart Protection in Lymphoma Treatments — Beth Israel Deaconess Medical Center
- Study on Genetically Modified T Cells Targeting CD22 for Children and Young Adults with Difficult-to-Treat Leukemia or Lymphoma — Seattle Children's Hospital
- Study on Valemetostat with Rituximab and Lenalidomide for Treating Relapsed or Refractory Follicular Lymphoma — M.D. Anderson Cancer Center
- A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma — Jennifer Crombie, MD
- Phase II Study of Loncastuximab Tesirine for Patients with Large B-Cell Lymphoma After CAR T-Cell Therapy — M.D. Anderson Cancer Center
- Study on Epcoritamab with Lenalidomide and Tafasitamab for Treating Diffuse Large B Cell Lymphoma — Memorial Sloan Kettering Cancer Center
- Study on Mosunetuzumab for People with Follicular Lymphoma — Memorial Sloan Kettering Cancer Center
- Study of Pembrolizumab in Children with Advanced Solid Tumors or Lymphoma — Merck Sharp & Dohme LLC
- Study on Repotrectinib for Children and Young Adults with Specific Genetic Changes in Cancer — Turning Point Therapeutics, Inc.
- Study on Ultra Low Dose Radiation Therapy for Treating Marginal Zone Lymphoma — M.D. Anderson Cancer Center
- Study Comparing Glofitamab Alone to Other Treatments for Relapsed or Hard-to-Treat Mantle Cell Lymphoma — Hoffmann-La Roche
- Study on the Safety and Effects of Eflapegrastim in Children with Solid Tumors or Lymphomas Undergoing Chemotherapy — Spectrum Pharmaceuticals, Inc
- Study on Fadraciclib for Patients with Advanced Solid Tumors and Lymphoma — Cyclacel Pharmaceuticals, Inc.
- Study on Using Donor Stem Cell Transplant with T and B Cell Depletion for Blood Cancers — Children's Hospital of Philadelphia
- AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies. — AstraZeneca
- Study on CD30biAb-AATC for Treating CD30+ Cancers — Medical College of Wisconsin
- Study on Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma — M.D. Anderson Cancer Center
- Study on Using Donor Blood Stem Cells for Transplant: Focusing on Immune System Checkpoints — Dartmouth-Hitchcock Medical Center
- Study on HLA-Mismatched Unrelated Donor Stem Cell Transplant with Post-Transplant Cyclophosphamide — Center for International Blood and Marrow Transplant Research
- Study on HLA-Mismatched Unrelated Donor Stem Cell Transplant with Reduced Cyclophosphamide for Graft Versus Host Disease Prevention — Center for International Blood and Marrow Transplant Research
- Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation — M.D. Anderson Cancer Center
- Study on Isatuximab During Stem Cell Collection and Transplant for Patients with Multiple Myeloma and Lymphoma — Divaya Bhutani
- Study on Myeloablative Stem Cell Transplant with Donor for Blood Disorders — Masonic Cancer Center, University of Minnesota
- Study on Nivolumab for Treating Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and Non-Hodgkin Lymphomas — National Cancer Institute (NCI)
- Study on Odronextamab for Treating Low Tumor Volume Advanced Follicular Lymphoma — Gottfried von Keudell, MD PhD
- Study on Pembrolizumab and Chemotherapy for Untreated B Cell Lymphoma — University of Chicago
- Pilot Study on Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy — M.D. Anderson Cancer Center
- Study on PTCy, Sirolimus, and VIC-1911 to Prevent GVHD in Stem Cell Transplant Patients — Masonic Cancer Center, University of Minnesota
- Study on Rituximab and Venetoclax for Untreated Marginal Zone Lymphoma — Gottfried von Keudell, MD PhD
- Study on Combination Chemotherapy with Monoclonal Antibody Therapy for Newly Diagnosed Non-Hodgkin's Lymphoma — SWOG Cancer Research Network
- Study on CD30 CAR Therapy for Relapsed or Hard-to-Treat CD30+ Hodgkin and Non-Hodgkin Lymphoma — UNC Lineberger Comprehensive Cancer Center
- Study on Ruxolitinib for Treating Relapsed or Hard-to-Treat T or NK Cell Lymphoma — Memorial Sloan Kettering Cancer Center
- Study of VIP152, Venetoclax, and Prednisone (VVIP) in Treating Difficult or Returning Blood Cancers — National Cancer Institute (NCI)
- Study on T-Cell Therapy (EB103) for Adults with Difficult or Returning B-Cell Non-Hodgkin's Lymphoma — Estrella Biopharma, Inc.
- Study on Tazemetostat Combined with CHOP Chemotherapy for First-Line Treatment of T-Cell Lymphoma — Eric Jacobsen, MD
- Study on Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) for Treating B-cell Lymphoma That Has Returned or Not Improved — National Cancer Institute (NCI)
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Lymphoma to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.